{"id":3908,"date":"2017-01-04T11:12:31","date_gmt":"2017-01-04T11:12:31","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/"},"modified":"2017-01-04T11:12:31","modified_gmt":"2017-01-04T11:12:31","slug":"nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/","title":{"rendered":"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA."},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Det amerikanska patentverket (\u201dUSPTO\u201d) har utf\u00e4rdat ett s\u00e5 kallat Notice of Allowance avseende Nanexa AB:s Antifungiella bel\u00e4ggning.\u00a0<\/strong><\/p>\n<\/div>\n<p>Patentet med titeln \u201dPolymeric protective layer\u201d och ans\u00f6kningsnummer 13\/824,398 omfattar produkten, metoden f\u00f6r tillverkning av produkten samt dess anv\u00e4ndande. Patentet inneb\u00e4r ett skydd minst till och med 2030. Notice of Allowance inneb\u00e4r i korthet att USPTO kommer att godk\u00e4nna bolagets patentans\u00f6kan. Innan slutgiltigt patent kan meddelas kvarst\u00e5r dock n\u00e5gra f\u00e5 administrativa \u00e5tg\u00e4rder.<\/p>\n<p>VD David Westberg kommenterar.<\/p>\n<p>\u201dNanexas antifungiella bel\u00e4ggning skapar ett skydd mot svampinv\u00e4xt i materialet. Detta utan fris\u00e4ttning av aktiv antimikrobiell substans, vilket ger medicinska implantat en l\u00e4ngre livsl\u00e4ngd. Nu n\u00e4r patentans\u00f6kan f\u00f6r den antifungiella bel\u00e4ggning formellt godk\u00e4nns i USA har vi uppn\u00e5tt ett viktigt delm\u00e5l f\u00f6r kommersialiseringen av teknologin. \u00a0Ut\u00f6ver USA-patentet har vi ocks\u00e5 en ans\u00f6kan under granskning hos Europapatentverket.\u201d<\/p>\n<p><span>F\u00f6r mer information kontakta:<\/span><\/p>\n<p><span>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<\/span><\/p>\n<p><span>?Telefon: 0709 -42 83 03?<\/span><\/p>\n<p><span>E-post:\u00a0<\/span><a href=\"mailto:david.westberg@nanexa.se\" rel=\"nofollow\"><span>david.westberg@nanexa.se<\/span><\/a>\u00a0<\/p>\n<p><a href=\"http:\/\/www.nanexa.se\/\" rel=\"nofollow\"><span>www.nanexa.se<\/span><\/a>\u00a0<\/p>\n<p><span>Om Nanexa AB (publ)<\/span><\/p>\n<p><span>Nanexa AB \u00e4r ett h\u00f6gteknologiskt forskningsf\u00f6retag som utvecklar och marknadsf\u00f6r produkter inom nanoteknologi. Bolagets fokus ligger p\u00e5 PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal omr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa samarbetsavtal med bland andra AstraZeneca, Uppsala universitet och Karolinska Institutet.<\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/aktietorget.blob.core.windows.net\/press\/news\/nanexa\/81656\/610708.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Det amerikanska patentverket (&#8221;USPTO&#8221;) har utf\u00e4rdat ett s\u00e5 kallat Notice of Allowance avseende Nanexa AB:s Antifungiella bel\u00e4ggning.<\/p>\n","protected":false},"template":"","class_list":["post-3908","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA. - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA. - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Det amerikanska patentverket (&quot;USPTO&quot;) har utf\u00e4rdat ett s\u00e5 kallat Notice of Allowance avseende Nanexa AB:s Antifungiella bel\u00e4ggning.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\\\/\",\"name\":\"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA. - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2017-01-04T11:12:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA. - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA. - Nanexa AB","og_description":"Det amerikanska patentverket (\"USPTO\") har utf\u00e4rdat ett s\u00e5 kallat Notice of Allowance avseende Nanexa AB:s Antifungiella bel\u00e4ggning.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/","name":"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA. - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2017-01-04T11:12:31+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-forhandsbesked-om-godkant-patent-i-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa erh\u00e5ller f\u00f6rhandsbesked om godk\u00e4nt patent I USA."}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}